Overview
electroCore Q3 revenue grows 33% yr/yr, beating analyst expectations
Company raises FY 2025 revenue guidance to $31.5 mln - $32.5 mln
Prescription sales growth driven by VA market and wellness products
Outlook
Company raises FY 2025 revenue guidance to $31.5 mln - $32.5 mln
Company expects to reach $12 mln in quarterly revenue by H2 2026
Company plans targeted sales and marketing investments for 2025
Result Drivers
VA MARKET GROWTH - Prescription sales in Veteran Affairs (VA) market drove revenue increase, with gammaCore and Quell Fibromyalgia showing strong growth
WELLNESS PRODUCTS - Truvaga wellness product sales hit record high, contributing to revenue growth
INCREASED SALES AND MARKETING - Greater investment in sales and marketing supported revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $8.69 mln | $7.84 mln (3 Analysts) |
Q3 Net Income | -$3.41 mln | ||
Q3 Operating Income | Beat | -$2.88 mln | -$3.22 mln (3 Analysts) |
Q3 Pretax Profit | Miss | -$3.41 mln | -$3.23 mln (3 Analysts) |
Q3 Gross Profit | $7.47 mln | ||
Q3 Operating Expenses | $10.35 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for electroCore, Inc. is $23.40, about 78.8% above its November 4 closing price of $4.95
Press Release: ID:nGNX69fmNG
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)